IMMUTEP LIMITED — Interim / Quarterly Report 2012

Apr 26, 2012

==> picture [215 x 40] intentionally omitted <==

ASX/Media Release (Code: PRR) 27 April 2012

QUARTERLY ACTIVITY REPORT For Quarter ending 31 March 2012

Prima BioMed (Prima) (ASX: PRR; NASDAQ: PBMD) today released its Appendix 4C – Quarterly Report for the three month period ending 31 March 2012.

The cash balance as of 31 March 2012 was A$ 42.8 million. The majority of funds spent during the quarter are related to development activities of Prima’s lead product Cvac[TM] .

Business highlights from the quarter:

• TGA grants Manufacturing License for CVac™ in Australia

• Commencement of ovarian cancer patient enrolment for CANVAS

• Registration Statement filed for NASDAQ listing

• Japanese patent granted for Cripto-1 antibody

For more details about these highlights, please refer to Prima’s previous releases on the ASX website.

Prima BioMed Ltd Level 7, 151 Macquarie Street, Sydney 2000 Ph: +61 (0) 2 9276 1224 Fax: +61 (0) 2 9276 1284 www.primabiomed.com.au ABN: 90 009 237 889

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Appendix 4C – 3[rd] Quarter

Quarterly Report

For Entities Admitted on the Basis of Commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of Entity:
Prima BioMed Ltd (ASX:PRR)
ABN: 90 009 237 889	Quarter Ended (“Current Quarter”)
90 009 237 889	31 March 2012

Consolidated Statement of Cash Flows

	Current Quarter	Year-to-Date
Cash flows related to operating activities	$A’000	$A’000
1.1 Receipts from customers 1.2 Payments for (a) staff costs (b) advertising and marketing (c) research and development (d) leased assets (e) other working capital 1.3 Dividends received 1.4 Interest and other items of a similar nature received 1.5 Interest and other costs of finance paid 1.6 Income taxes benefit 1.7 Other - grants received	13 (800) (86) (4,026) - (473) - 625 - - -	13 (2,053) (185) (11,821) - (2,872) - 1,726 - 764 -
Net operating cash flows	(4,747)	(14,428)

• See chapter 19 for defined terms.

30/9/2001

Appendix 4C Page 1

Appendix 4C Quarterly report for entities admitted on the basis of commitments

	Current Quarter $A’000	Year-to-Date $A’000
1.8 Net operating cash flows (carried forward)	(4,747)	(14,428)
Cash flows related to investing activities
1.9 Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.10 Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.11 Loans to other entities 1.12 Loans repaid by other entities 1.13 Other(provide details if material)	- - - (218) - - - - - - - - -	- - - (538) - - - - - - - - -
Net investing cash flows	(218)	(538)
1.14 Total operating and investing cash flows	(4,965)	(14,966)
Cash flows related to financing activities
1.15 Proceeds from issues of shares, options, etc. 1.16 Transfer of shares 1.17 Proceeds from borrowings net finance costs 1.18 Repayment of borrowings 1.19 Dividends paid 1.20 Other - capital raisingcosts	172 - - - - -	1,821 - - - - -
Net financing cash flows	172	1,821
Net increase (decrease) in cash held	(4,793)	(13,145)
1.21 Cash at beginning of quarter/year to date 1.22 Exchange rate adjustments to item 1.21	47,475 142	55,919 50
1.23 Cash at end of quarter	42,824	42,824

• See chapter 19 for defined terms.

30/9/2001

Appendix 4C Page 2

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Payments to Directors of the Entity and Associates of the Directors

Payments to Related Entities of the Entity and Associates of the Related Entities

1.24 1.25		Current Quarter
		$A'000
	Aggregate amount of payments to the parties included in item 1.2 Aggregate amount of loans to the parties included in item 1.11	277 -

• 1.26 Explanation necessary for an understanding of the transactions

Directors’ fees and consulting fees at normal commercial rates

Non-Cash Financing and Investing Activities

• 2.1 Details of financing and investing transactions which have had a material affect on consolidated Assets and liabilities but did not involve cash flows

• 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Financing Facilities Available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

3.1 3.2		Amount Available	Amount Used
		$A’000	$A’000
	Loan facilities	-	-
	Credit standby arrangements	12,000*	-

Note:

• 3.2 $12 million equity drawdown facility in place with Foretrend Securities Pty Ltd.

• See chapter 19 for defined terms.

30/9/2001

Appendix 4C Page 3

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Reconciliation of Cash

Reco (as s to th 4.1 4.2 4.3 4.4	nciliation of cash at the end of the quarter hown in the consolidated statement of cash flows) e related items in the accounts is as follows.	Current Quarter	Previous Quarter
		$A’000	$A’000
	Cash on hand and at bank	2,963	601
	Deposits at call	2,258	9,961
	Bank overdraft	-	-
	Other (Term Deposit)	37,303	36,913
	Total: Cash at end of quarter(item 1.23)	42,824	47,475

Acquisitions and Disposals of Business Entities

5.1 5.2 5.3 5.4 5.5	Name of entity	Acquisitions	Disposals
		(Item 1.9(a))	(Item 1.10(a))
		-	-
	Place of incorporation or registration	-	-
	Consideration for acquisition or disposal	-	-
	Total net assets	-	-
	Nature of business	-	-

Compliance Statement

• 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

• 2 This statement does give a true and fair view of the matters disclosed.

Sign Here:

Date: Friday 27[th] April 2012

==> picture [94 x 55] intentionally omitted <==

Company Secretary

Print Name: Ian Bangs

• See chapter 19 for defined terms.

30/9/2001

Appendix 4C Page 4

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Notes

1. The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2. The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below.

3. 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss

4. 9.2 - itemised disclosure relating to acquisitions

5. 9.4 - itemised disclosure relating to disposals

6. 12.1(a) - policy for classification of cash items

7. 12.3 - disclosure of restrictions on use of cash

8. 13.1 - comparative information

9. Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

10. See chapter 19 for defined terms.

30/9/2001

Appendix 4C Page 5